Optimizing IV Gentamicin in JEB

• ClinicalTrials.gov Identifier: NCT04140786
• Recruitment Status: Recruiting
• First Posted: October 28, 2019
• Last Update Posted: November 6, 2019
• Sponsor: University of Southern California
• Information provided by (Responsible Party): David Woodley, University of Southern California

Study Description

Brief Summary:

Herlitz junctional epidermolysis bullosa (H-JEB), an incurable and fatal inherited skin disease, is caused by loss-of-function mutations in LAMA3, LAMB3 and LAMC2. These mutations result in diminished laminin 332 and epidermal-dermal adherence. 85% of JEB patients have nonsense mutations in LAMA3, LAMB3, or LAMC2, suggesting that H-JEB is a prime therapeutic target for nonsense suppression therapy. The investigators recently demonstrated in three patients that topical gentamicin created new and stable laminin 332 at the dermal-epidermal junction (DEJ), and also improved wound closure and skin quality. Furthermore, these preliminary studies showed that intravenous gentamicin also induced laminin 332 and transiently improved patients' clinical outcomes. No untoward side effects occurred. The investigators propose to optimize the intravenous gentamicin regimen including dosage and infusion schedules to enhance the therapeutic outcome. The milestones will be an increase of laminin 332 in the patients' DEJ, improvement in EB Disease Activity Scores, and no gentamicin-associated side effects.

Condition or disease	Intervention/treatment	Phase
Junctional Epidermolysis Bullosa	Drug: Gentamicin Sulfate, Injectable	Phase 1; Phase 2

Detailed Description:

RATIONALE:

Herlitz junctional epidermolysis bullosa (H-JEB), an incurable and fatal inherited skin disease, is caused by loss-of-function mutations in LAMA3, LAMB3 and LAMC2. These mutations result in diminished laminin 332 and epidermal-dermal adherence. 85% of JEB patients have nonsense mutations in LAMA3, LAMB3, or LAMC2, suggesting that H-JEB is a prime therapeutic target for nonsense suppression therapy. The investigators recently demonstrated in three patients that topical gentamicin created new and stable laminin 332 at the dermal-epidermal junction (DEJ), and also improved wound closure and skin quality. Furthermore, these preliminary studies showed that intravenous gentamicin also induced laminin 332 and transiently improved patients' clinical outcomes. No untoward side effects occurred. The investigators propose to optimize the intravenous gentamicin regimen including dosage and infusion schedules to enhance the therapeutic outcome.

INTERVENTION:

There will be two study designs on JEB patients with nonsense mutation(s):

A. Short Term Daily IV Gentamicin Study: Three patients of any age with JEB caused by nonsense mutation(s) in the LAMA3 and LAMB3 genes will receive intravenous gentamicin (10 mgs/kg) daily for 24 days and then stop. Prior to treatment and at 1 month and 3 months post treatment, selected skin test sites will have skin biopsies and the specimens evaluated for the expression of laminin 332 at the dermal-epidermal junction by direct immunofluorescent staining of the skin. Safety parameters such as physical exam, review of systems, laboratory tests, audiometry, and renal function at the same time periods.

B. Long Term Biweekly IV Gentamicin Study: Three patients of any age with JEB caused by nonsense mutation(s) in the LAMA3 and LAMB3 genes will receive intravenous gentamicin (10 mgs/kg) twice weekly for 3 months (24 total infusions) and then stop. Before and after evaluations will be performed and will be the same as those in the short term intravenous study outlined above.

STUDY POPULATION:

3 adults/children for who have JEB due to nonsense mutations in the LAMA3 or LAMB3 gene for each intervention arm.

STUDY ENDPOINTS OR OUTCOMES Analysis of safety parameters, wound healing, and generation of new laminin 332 at the dermal-epidermal junction of the skin by direct immunofluorescent stain.

FOLLOW-UP Participants will be followed out to 90 days post treatment

STATISTICS Without treatment, these JEB patients have little or no laminin A3/laminin B3/laminin 332 at their dermal-epidermal junction. The expression of any newly generated laminin 332 will be measure against normal human skin (100%) by NIH Image J software.

PLANS FOR ANALYSIS Safety parameters are outlined above and will be examined at baseline and after each patient visit. Efficacy parameters outlined above will be measured at baseline and at post treatment days 30 and 90.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 6 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Optimization of Intravenous Gentamicin Treatment to Restore Functional Laminin 332 in JEB Patients With Nonsense Mutations
• Actual Study Start Date: October 31, 2019
• Estimated Primary Completion Date: April 2021
• Estimated Study Completion Date: November 2021

Arms and Interventions

Arm	Intervention/treatment
Experimental: Daily IV Gentamicin; Once daily (for 24 days) IV infusions of 10 mg/kg gentamicin delivered over a 30-60 minute period.	Drug: Gentamicin Sulfate, Injectable; 10mg/kg prepared from commercially available stock (typically Kabi Pharmaceuticals) by licensed pharmacists.; Other Name: Gentamicin, Garamycin
Experimental: Biweekly IV Gentamicin; Twice weekly (for 3 months or 24 total) IV infusions of 10 mg/kg gentamicin delivered over a 30-60 minute period.	Drug: Gentamicin Sulfate, Injectable; 10mg/kg prepared from commercially available stock (typically Kabi Pharmaceuticals) by licensed pharmacists.; Other Name: Gentamicin, Garamycin

Outcome Measures

Primary Outcome Measures :

1. Laminin 332 Expression in Skin [ Time Frame: 3 months ]
   Expression of laminin 332 as assessed by immunofluorescence of patient skin sections as a percentage of normal skin.
2. Safety (Ototoxicity) [ Time Frame: 3 months ]
   Testing for any gentamicin-associated auditory impairment as assessed by pure-tone audiometry assessments.
3. Safety (Nephrotoxicity) [ Time Frame: 3 months ]
   Testing for any gentamicin-associated renal impairment as assessed by calculated creatinine clearance.
4. Safety (Autoimmune Response) [ Time Frame: 3 months ]
   Testing for the presence of auto antibodies to newly formed laminin 332 in response to gentamicin as assessed by specific ELISA.

Secondary Outcome Measures :

1. Wound Healing [ Time Frame: 3 months ]
   Size of skin wounds selected for monitoring at baseline as assessed by computer assisted planimetry of photographs.
2. Epidermolysis Bullosa Disease and Activity and Scarring Index (EBDASI) [ Time Frame: 3 months ]
   A disease scoring system designed for patients with epidermolysis bullosa (EB).

Eligibility Criteria

• Ages Eligible for Study: Child, Adult, Older Adult
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• JEB patients with nonsense mutations in LAMB3 or LAMA3 in either one or two alleles
• Immunofluorescence (IF) analysis showing absence or decreased laminin 332 expression at their DEJ compared with normal skin.

Exclusion Criteria:

• Pre-existing known auditory impairment.
• Pre-existing known renal impairment.
• Pre-existing known allergies to aminoglycosides or sulfate compounds.
• Pregnancy.
• Recent exposure to systemic gentamicin within the past 6 weeks.
• Current use of any medications with known potential ototoxicity or nephrotoxicity.

Contacts and Locations

Contacts

Contact: David T Woodley, MD; (323) 442 0084; dwoodley@med.usc.edu

Locations

United States, California

University of Southern California; Recruiting

Los Angeles, California, United States, 90033

Contact: David Woodley, MD 323-865-0956 dwoodley@med.usc.edu

Contact: Mei Chen, Ph.D 3238650621 chenm@usc.edu

Sponsors and Collaborators

University of Southern California

Investigators

• Principal Investigator: Mei Chen, PhD; University of Southern California

More Information

• Responsible Party: David Woodley, Professor of Dermatology, Keck School of Medicine, University of Southern California
• ClinicalTrials.gov Identifier: NCT04140786
• Other Study ID Numbers: HS-19-00760
• First Posted: October 28, 2019
• Last Update Posted: November 6, 2019
• Last Verified: November 2019

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

Keywords provided by David Woodley, University of Southern California:

Nonsense mutation

Additional relevant MeSH terms:

Epidermolysis Bullosa; Epidermolysis Bullosa, Junctional; Gentamicins; Skin Abnormalities; Congenital Abnormalities; Skin Diseases, Genetic; Genetic Diseases, Inborn; Skin Diseases; Skin Diseases, Vesiculobullous; Anti-Bacterial Agents; Anti-Infective Agents; Protein Synthesis Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action